title: Effect of n-3 polyunsaturated fatty acids and rosuvastatin in patients with heart failure: results of the GISSI-HF trial.
abstract: Epidemiological, experimental studies and post hoc analyses of randomized trials suggested that n-3 polyunsaturated fatty acids (PUFA) and statins could be beneficial in chronic heart failure. Two double-blind, placebo-controlled, randomized clinical trials investigated the efficacy and safety of n-3 PUFA 1 g daily (R1) and rosuvastatin 10 mg daily (R2) in patients with heart failure. In total, 6975 and 4574 patients were randomized in R1 and R2, respectively; the main reason for excluding patients from R2 being the open-label administration of statin treatment. Primary end points were death, and death or admission to hospital for cardiovascular reasons. n-3 PUFA, but not rosuvastatin, significantly decreased the two coprimary end points: 56 and 44 patients needed to be treated with n-3 PUFA for a median duration of 3.9 years to avoid one death or one cumulative event. Both drugs were safe and were tolerated. A simple and safe treatment with n-3 PUFA provides a beneficial advantage in patients with heart failure in a context of usual care.
authors: Consorzio Mario Negri Sud, Santa Maria Imbaro, Italy. marchioli@negrisud.it
authors: Roberto
authors: R
authors: Marchioli
authors: Giacomo
authors: G
authors: Levantesi
authors: Maria G
authors: MG
authors: Silletta
authors: Simona
authors: S
authors: Barlera
authors: Marino
authors: M
authors: Bernardinangeli
authors: Emanuele
authors: E
authors: Carbonieri
authors: Francesco
authors: F
authors: Cosmi
authors: Maria G
authors: MG
authors: Franzosi
authors: Roberto
authors: R
authors: Latini
authors: Donata
authors: D
authors: Lucci
authors: Aldo Pietro
authors: AP
authors: Maggioni
authors: Luciano
authors: L
authors: Moretti
authors: Gian L
authors: GL
authors: Nicolosi
authors: Maurizio
authors: M
authors: Porcu
authors: Maria G
authors: MG
authors: Rossi
authors: Gianni
authors: G
authors: Tognoni
authors: Luigi
authors: L
authors: Tavazzi
mesh_terms: D000368:Aged; D004311:Double-Blind Method; D015525:Fatty Acids, Omega-3 / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005464:Fluorobenzenes / Q000009:adverse effects / Q000627:therapeutic use*; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D015525:Fatty Acids, Omega-3; D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium